Supplementary Material

Effects of Cocoa Extract Supplementation and Multivitamin/Multimineral Supplements on Self-Reported Fractures in the Cocoa Supplement and Multivitamins Outcomes Study (COSMOS)

Randomized Clinical Trial

Carolyn J. Crandall, MD, MS, MACP, Eunjung Kim, MS, Sharon Chou, MD, Dana Ratnarajah, BS, Nancy R. Cook, ScD, Allison Clar, BS, Howard D. Sesso, ScD, MPH, JoAnn E. Manson, MD, DrPH, Meryl S. LeBoff, MD

| Item | Page number |
|---|----------------|
| Supplemental Table 1. Composition of the COSMOS Centrum Silver Supplement | 2 |
| Supplemental Table 2. Baseline characteristics of participants in the overall COSMOS cohort (21,442), according to randomized treatment assignment: Cocoa Extract Supplementation vs. Placebo | 3 |
| Supplemental Table 3. Baseline characteristics of participants in the overall COSMOS cohort (21,442), according to randomized treatment assignment: Multivitimain/Multimineral Supplement vs. Placebo | 6 |
| Supplemental Table 4. Locations of Prevalent Fractures Prior to Trial Enrollment | 9 |
| Supplemental Table 5. Effects of Multivitamin/Multimineral Supplementation (vs. Placebo) on Incident Fracture by Tertile of Alternative Health Eating Index Score, According to Fracture Location | 10 |
| Supplemental Table 6. Effects of Multivitamin/Multimineral Supplementation (vs. Placebo) on Incident Fracture by Self-Rated General Health, According to Fracture Location | 11 |

Supplemental Table 1. Composition of the COSMOS Centrum Silver Supplement

| Vitamin or mineral (units) | Amount | % Daily Value (* Daily Value not established) |
|------------------------------|----------------|---|
| Biotin (μg) | 30 | 10 |
| Boron (µg) | - | - |
| Calcium (mg) | 220 | 22 |
| Chloride (mg) | 72 | 2 |
| Chromium (µg) | 50 | 42 |
| Copper (mg) | 0.5 | 25 |
| Folic Acid (µg) | 400 | 100 |
| Iodine (µg) | 150 | 100 |
| Iron (mg) | - | - |
| Lutein (µg) | 250 | * |
| Lycopene (µg) | 300 | * |
| Magnesium (mg) | 50 | 13 |
| Manganese (mg) | 2.3 | 115 |
| Molybdenum (μg) | 45 | 60 |
| Niacin (mg) | 20 | 100 |
| Nickel (µg) | 5 | * |
| Pantothenic Acid (mg) | 10 | 100 |
| Phosphorus (mg) | 20 | 2 |
| Potassium (mg) | 80 | 2 |
| Riboflavin (mg) | 1.7 | 100 |
| Selenium (µg) | 19 | 27 |
| Silicon (mg) | 2 | * |
| Thiamin (mg) | 1.5 | 100 |
| Vanadium (µg) | 10 | * |
| Vitamin A (IU) | 2500 | 50 |
| | 40% β-carotene | |
| Vitamin B ₁₂ (μg) | 25 | 417 |
| Vitamin B ₆ (mg) | 3 | 150 |
| Vitamin C (mg) | 60 | 100 |
| Vitamin D (IU) | 1000 | 250 |
| Vitamin E (IU) | 50 | 167 |
| Vitamin K (μg) | 30 | 38 |
| Zinc (mg) | 11 | 73 |

Supplemental Table 2. Baseline characteristics of participants in the overall COSMOS cohort (21,442), according to randomized treatment assignment: Cocoa Extract Supplementation vs. Cocoa Extract Placebo

| Variable | All | Cocoa Extract | Cocoa Extract Placebo |
|--|------------------|------------------|--------------------------|
| Demographic characteristics | | | |
| Age group, no. (%) | N=21,442 | | |
| 60-69 | 9224 (43.0%) | 4610 (43.0%) | 4614 (43.0%) |
| 70-74 | 5774 (26.9%) | 2886 (26.9%) | 2888 (26.9%) |
| 75-79 | 3751 (17.5%) | 1876 (17.5%) | 1875 (17.5%) |
| 80-84 | 1761 (8.2%) | 882 (8.2%) | 879 (8.2%) |
| ≥85 | 932 (4.4%) | 465 (4.3%) | 467 (4.4%) |
| Body Mass Index group, no. (%), kg/m ² | N=21,018 | | |
| <25 | 7070 (33.64%) | 3584 (34.12%) | 3486 (33.16%) |
| 25 to <30 | 8230 (39.16%) | 4062 (38.67%) | 4168 (39.65%) |
| ≥30 | 5718 (27.21%) | 2859 (27.22%) | 2859 (27.19%) |
| Medical Conditions | | | |
| Diabetes | N=21,433 | | |
| Yes | 2864 (13.36%) | 1417 (13.22%) | 1447 (13.50%) |
| Multiple Sclerosis | N=21,239 | | |
| Yes | 66 (0.31%) | 32 (0.30%) | 34 (0.32%) |
| Parkinson's Disease | N=21,278 | | |
| Yes | 81 (0.38%) | 33 (0.31%) | 48 (0.45%) |
| Medications (regular use) | | | |
| Use of diabetes medication | N=21,433 | | |
| Yes | 2233 (10.42%) | 1099 (10.26%) | 1134 (10.58%) |
| Use of selective serotonin reuptake inhibitors | N=21,116 | | |
| Yes | 1622 (7.68%) | 830 (7.85%) | 792 (7.51%) |
| Use of proton pump inhibitors | N=21,188 | | |
| Yes | 2424 (11.44%) | 1237 (11.66%) | 1187 (11.22%) |
| Use of corticosteroids | N=20,937 | | |
| Yes | 587 (2.80%) | 310 (2.96%) | 277 (2.65%) |
| Use of bone loss/osteoporosis medications* | N=21,095 | | |
| Yes | 1413 (6.70%) | 720 (6.83%) | 693 (6.57%) |
| Use of thyroid hormone | N=21,197 | | |
| Yes | 3761 (17.74%) | 1839 (17.35%) | 1922 (18.14%) |
| Behavioral Characteristics | | | |

| Variable | All | Cocoa Extract | Cocoa Extract Placebo |
|---|-------------------|------------------|--------------------------|
| Sleep, hrs | N=21,123 | | |
| <5 | 358 (1.69%) | 175 (1.66%) | 183 (1.73%) |
| 5 | 1264 (5.98%) | 638 (6.05%) | 626 (5.92%) |
| 6 | 4153 (19.66%) | 2035 (19.28%) | 2118 (20.04%) |
| 7 | 8053 (38.12%) | 4112 (38.97%) | 3941 (37.28%) |
| 8 | 5609 (26.55%) | 2735 (25.92%) | 2874 (27.19%) |
| 9 | 1476 (6.99%) | 749 (7.10%) | 727 (6.88%) |
| ≥10 | 210 (0.99%) | 109 (1.03%) | 101 (0.96%) |
| Physical Activity | | | |
| Flights of stairs climbed daily | N=21,019 | | |
| None | 5124 (24.38%) | 2533 (24.14%) | 2591 (24.62%) |
| 1-2 flights | 4647 (22.11%) | 2314 (22.05%) | 2333 (22.17%) |
| 3-4 flights | 3414 (16.24%) | 1703 (16.23%) | 1711 (16.26%) |
| 5-9 flights | 4051 (19.27%) | 2022 (19.27%) | 2029 (19.28%) |
| 10-14 flights | 2334 (11.10%) | 1190 (11.34%) | 1144 (10.87%) |
| 15 or more | 1449 (6.89%) | 732 (6.98%) | 717 (6.81%) |
| Usual walking pace | N=21,166 | | |
| Don't walk regularly | 2381 (11.25%) | 1161 (10.98%) | 1220 (11.51%) |
| Easy (less than 2 mph) | 3791 (17.91%) | 1871 (17.70%) | 1920 (18.12%) |
| Normal 2-2.9 mph | 9585 (45.28%) | 4792 (45.33%) | 4793 (45.24%) |
| Brisk 3-3.9 mph | 4919 (23.24%) | 2489 (23.55%) | 2430 (22.94%) |
| Very brisk 4 mph or faster | 490 (2.32%) | 258 (2.44%) | 232 (2.19%) |
| Physical Function limitations in past 2 weeks | | | |
| Climbing a flight of stairs without stopping (N=21,007) | | | |
| Extremely | 420 (2.00%) | 214 (2.04%) | 206 (1.96%) |
| Quite a bit | 459 (2.18%) | 226 (2.15%) | 233 (2.22%) |
| Moderately | 803 (3.82%) | 399 (3.80%) | 404 (3.85%) |
| Slightly | 2138 (10.18%) | 1048 (9.98%) | 1090 (10.38%) |
| Not at all | 17187 (81.82%) | 8618 (82.04%) | 8569 (81.59%) |
| Dressing yourself (N=21,103) | | | |
| Extremely | 23 (0.11%) | 10 (0.09%) | 13 (0.12%) |
| Quite a bit | 31 (0.15%) | 15 (0.14%) | 16 (0.15%) |

| Variable | All | Cocoa Extract | Cocoa Extract Placebo |
|---|-------------------|-------------------|--------------------------|
| Moderately | 91 (0.43%) | 44 (0.42%) | 47 (0.45%) |
| Slightly | 378 (1.79%) | 183 (1.73%) | 195 (1.85%) |
| Not at all | 20580 (97.52%) | 10299 (97.61%) | 10281 (97.43%) |
| Hurrying (as if to catch a bus) or jogging (N=20,954) | | | |
| Extremely | 913 (4.36%) | 454 (4.33%) | 459 (4.38%) |
| Quite a bit | 856 (4.09%) | 416 (3.97%) | 440 (4.20%) |
| Moderately | 1048 (5.00%) | 532 (5.08%) | 516 (4.93%) |
| Slightly | 2574 (12.28%) | 1312 (12.52%) | 1262 (12.05%) |
| Not at all | 15563 (74.27%) | 7768 (74.11%) | 7795 (74.44%) |
| Showering and bathing (N=21,111) | | | |
| Extremely | 33 (0.16%) | 16 (0.15%) | 17 (0.16%) |
| Quite a bit | 43 (0.20%) | 20 (0.19%) | 23 (0.22%) |
| Moderately | 138 (0.65%) | 71 (0.67%) | 67 (0.63%) |
| Slightly | 456 (2.16%) | 219 (2.07%) | 237 (2.25%) |
| Not at all | 20441 (96.83%) | 10229 (96.91%) | 10212 (96.74%) |
| Walking one block on level ground (N=21,043) | | | |
| Extremely | 239 (1.14%) | 117 (1.11%) | 122 (1.16%) |
| Quite a bit | 293 (1.39%) | 148 (1.41%) | 145 (1.38%) |
| Moderately | 478 (2.27%) | 242 (2.30%) | 236 (2.24%) |
| Slightly | 1204 (5.72%) | 585 (5.56%) | 619 (5.88%) |
| Not at all | 18829 (89.48%) | 9425 (89.62%) | 9404 (89.34%) |
| Doing yard work, housework, or carrying groceries (N=21,058) | | | |
| Extremely | 248 (1.18%) | 125 (1.19%) | 123 (1.17%) |
| Quite a bit | 419 (1.99%) | 188 (1.78%) | 231 (2.19%) |
| Moderately | 941 (4.47%) | 473 (4.49%) | 468 (4.45%) |
| Slightly | 2718 (12.91%) | 1399 (13.28%) | 1319 (12.53%) |
| Not at all | 16732 (79.46%) | 8348 (79.26%) | 8384 (79.66%) |
| General Health, Self-reported | N=20,975 | | |
| Excellent | 5633 (26.86%) | 2859 (27.25%) | 2774 (26.46%) |
| Very Good/Good | 14709 (70.13%) | 7321 (69.79%) | 7388 (70.46%) |
| Fair/Poor | 633 (3.02%) | 310 (2.96%) | 323 (3.08%) |

Supplemental Table 3. Baseline characteristics of participants in the overall COSMOS cohort (21,442), according to randomized treatment assignment: Multivitamin/Multimineral Supplementation vs. Placebo

| Variable | All ¹ | Multivitamin/Multimineral Supplementation | Placebo |
|--|------------------|--|-----------------|
| Demographic characteristics | | | |
| Age group, no. (%) | | | |
| 60-69 | 9224 (43.0%) | 4611 (43.0%) | 4613 (43.0%) |
| 70-74 | 5774 (27.0%) | 2886 (26.9%) | 2888 (26.9%) |
| 75-79 | 3751 (17.5%) | 1875 (17.5%) | 1876 (17.5%) |
| 80-84 | 1761 (8.2%) | 889 (8.3%) | 872 (8.1%) |
| ≥85 | 932 (4.4%) | 459 (4.3%) | 473 (4.4%) |
| Body Mass Index group, no. (%), kg/m ² | | | |
| <25 | 7070 (33.6%) | 3533 (33.7%) | 3537 (33.6%) |
| 25 to <30 | 8230 (39.16%) | 4166 (39.7%) | 4064 (38.6%) |
| ≥30 | 5718 (27.21%) | 2800 (26.7%) | 2918 (27.7%) |
| Medical Conditions | | | |
| Diabetes | N=21433 | | |
| Yes | 2864 (13.4%) | 1415 (13.2%) | 1449 (13.5%) |
| Multiple Sclerosis | N=21239 | | |
| Yes | 66 (0.3%) | 38 (0.4%) | 28 (0.3%) |
| Parkinson's Disease | N=21278 | | |
| Yes | 81 (0.4%) | 32 (0.3%) | 49 (0.5%) |
| Medications (regular use) | | | |
| Use of diabetes medication | N=21433 | | |
| Yes | 2233 (10.4%) | 1098 (10.3%) | 1135 (10.6%) |
| Use of selective serotonin reuptake inhibitors | N=21,116 | | |
| Yes | 1622 (7.7%) | 767 (7.3%) | 855 (8.1%) |
| Use of proton pump inhibitors | N=21,188 | | |
| Yes | 2424 (11.4%) | 1178 (11.1%) | 1246 (11.8%) |
| Use of corticosteroids | N=20,937 | | |
| Yes | 587 (2.8%) | 265 (2.5%) | 322 (3.1%) |

_

¹ Information was lacking regarding ethnicity in 863 participants, body mass index in 424 participants, and leisure time physical activity in 258 participants.

| Variable | All ¹ | Multivitamin/Multimineral Supplementation | Placebo |
|---|------------------|--|-----------------|
| Use of prescription osteoporosis medications ² | N=21,095 | Συργοιιού | |
| Yes | 1413 (6.7%) | 685 (6.5%) | 728 (6.9%) |
| Use of thyroid hormone | N=21,197 | | |
| Yes | 3761 (17.7%) | 1881 (17.8%) | 1880 (17.7%) |
| Behavioral Characteristics | | | |
| Sleep, hrs | N=21123 | | |
| <5 | 358 (1.7%) | 181 (1.7%) | 177 (1.7%) |
| 5 | 1264 (6.0%) | 647 (6.1%) | 617 (5.9%) |
| 6 | 4153 (19.7%) | 2073 (19.6%) | 2080 (19.7%) |
| 7 | 8053 (38.1%) | 3991 (37.8%) | 4062 (38.5%) |
| 8 | 5609 (26.6%) | 2825 (26.7%) | 2784 (26.4%) |
| 9 | 1476 (7.0%) | 750 (7.1%) | 726 (6.9%) |
| ≥10 | 210 (1.0%) | 105 (1.0%) | 105 (1.0%) |
| Physical Activity | | | |
| Flights of stairs climbed daily | N=21019 | | |
| None | 5124 (24.4%) | 2558 (24.3%) | 2566 (24.4%) |
| 1-2 flights | 4647 (22.1%) | 2307 (21.9%) | 2340 (22.3%) |
| 3-4 flights | 3414 (16.2%) | 1715 (16.3%) | 1699 (16.2%) |
| 5-9 flights | 4051 (19.3%) | 2020 (19.2%) | 2031 (19.3%) |
| 10-14 flights | 2334 (11.1%) | 1185 (11.3%) | 1149 (10.9%) |
| 15 or more | 1449 (6.9%) | 735 (7.0%) | 714 (6.8%) |
| Usual walking pace | N=21166 | | |
| Don't walk regularly | 2381 (11.3%) | 1193 (11.3%) | 1188 (11.2%) |
| Easy (less than 2 mph) | 3791 (18.0%) | 1901 (18.0%) | 1890 (17.9%) |
| Normal 2-2.9 mph | 9585 (45.3%) | 4771 (45.1%) | 4814 (45.5%) |
| Brisk 3-3.9 mph | 4919 (23.2%) | 2484 (23.5%) | 2435 (23.0%) |
| Very brisk 4 mph or faster | 490 (2.3%) | 238 (2.3%) | 252 (2.4%) |
| Physical Function limitations in past | | | |
| 2 weeks Climbing a flight of stairs without | | | |
| stopping | N=21007 | | |
| Extremely | 420 (2.0%) | 215 (2.1%) | 205 (2.0%) |

² alendronate, risedronate, ibandronate, zoledronic acid, denosumab, teriparatide, raloxifene, or calcitonin

| Variable | All ¹ | Multivitamin/Multimineral Supplementation | Placebo |
|---|------------------|--|------------------|
| Quite a bit | 459 (2.2%) | 234 (2.2%) | 225 (2.1%) |
| Moderately | 803 (3.8%) | 390 (3.7%) | 413 (3.9%) |
| Slightly | 2138 (10.2%) | 1037 (9.9%) | 1101 (10.5%) |
| Not at all | 17187 (81.8%) | 8623 (82.1%) | 8564 (81.5%) |
| Dressing yourself | (N=21,103) | | |
| Extremely | 23 (0.1%) | 16 (0.2%) | 7 (0.1%) |
| Quite a bit | 31 (0.2%) | 18 (0.2%) | 13 (0.1%) |
| Moderately | 91 (0.4%) | 44 (0.4%) | 47 (0.5%) |
| Slightly | 378 (1.8%) | 191 (1.8%) | 187 (1.8%) |
| Not at all | 20580 (97.5%) | 10284 (97.5%) | 10296 (97.6%) |
| Hurrying (as if to catch a bus) or jogging | (N=20,954) | | |
| Extremely | 913 (4.4%) | 459 (4.4%) | 454 (4.3%) |
| Quite a bit | 856 (4.1%) | 432 (4.1%) | 424 (4.1%) |
| Moderately | 1048 (5.0%) | 499 (4.8%) | 549 (5.2%) |
| Slightly | 2574 (12.3%) | 1252 (12.0%) | 1322 (12.6%) |
| Not at all | 15563 (74.3%) | 7837 (74.8%) | 7726 (73.8%) |
| Showering and bathing | (N=21,111) | | |
| Extremely | 33 (0.2%) | 22 (0.2%) | 11 (0.1%) |
| Quite a bit | 43 (0.2%) | 24 (0.2%) | 19 (0.2%) |
| Moderately | 138 (0.7%) | 71 (0.7%) | 67 (0.6%) |
| Slightly | 456 (2.2%) | 224 (2.1%) | 232 (2.2%) |
| Not at all | 20441 (96.8%) | 10218 (96.8%) | 10223 (96.9%) |
| Walking one block on level ground | (N=21,043) | | |
| Extremely | 239 (1.1%) | 124 (1.2%) | 115 (1.1%) |
| Quite a bit | 293 (1.4%) | 152 (1.5%) | 141 (1.3%) |
| Moderately | 478 (2.3%) | 239 (2.3%) | 239 (2.3%) |
| Slightly | 1204 (5.7%) | 573 (5.5%) | 631 (6.0%) |
| Not at all | 18829 (89.5%) | 9429 (89.7%) | 9400 (89.3%) |
| Doing yard work, housework, or carrying groceries | (N=21,058) | | |
| Extremely | 248 (1.2%) | 129 (1.2%) | 119 (1.1%) |
| Quite a bit | 419 (2.0%) | 217 (2.1%) | 202 (1.9%) |
| Moderately | 941 (4.5%) | 466 (4.4%) | 475 (4.5%) |
| Slightly | 2718 (12.9%) | 1320 (12.5%) | 1398 (13.3%) |
| Not at all | 16732 (79.5%) | 8399 (79.8%) | 8333 (79.2%) |

Supplemental Table 4. Locations of Prevalent Fractures Prior to Trial Enrollment

| Fracture | Cocoa | Cocoa extract | Multivitamin/Multimineral | MVM |
|-----------|---------------|---------------|---------------------------|-------------|
| location | extract group | placebo group | (MVM) Group (10,720) | Placebo |
| | (n = 10,719) | (n = 10,723) | | group (n = |
| | | | | 10,722) |
| | n (%) | n (%) | n (%) | n (%) |
| Hip | 135 (6.3) | 116 (5.5%) | 124 (6.0%) | 127 (5.8%) |
| Clinical | 111 (5.2%) | 82 (3.9%) | 83 (4.0%) | 110 (5.1%) |
| spine | | | | |
| Lower | 412 (19.1%) | 409 (19.5%) | 392 (18.9%) | 429 (19.7%) |
| arm | | | | |
| Upper | 185 (8.6%) | 180 (8.6%) | 192 (9.3%) | 173 (8.0%) |
| arm | | | | |
| Lower leg | 277 (12.9%) | 310 (14.8%) | 298 (14.4%) | 289 (13.3%) |
| Upper leg | 60 (2.8%) | 78 (3.7%) | 68 (3.3%) | 70 (3.2%) |
| Foot | 582 (27.0%) | 579 (27.7%) | 559 (27.0%) | 602 (27.7%) |
| Other | 861 (40.0%) | 803 (38.4) | 825 (39.8%) | 839 (38.6%) |

Supplemental Table 5. Effects of Multivitamin/Multimineral Supplementation (vs. Placebo) on Incident Fracture by Tertile of Alternative Healthy Eating Index Score, According to Fracture Location

| | | # Events | HR (95% CI) |
|--------------------|-----------------|----------|------------------|
| Clinical | | | |
| | Lowest tertile | 561 | 0.99 (0.84-1.17) |
| | Middle tertile | 629 | 1.02 (0.87-1.20) |
| | Highest tertile | 660 | 1.27 (1.09-1.48) |
| Hip | | | |
| | Lowest tertile | 52 | 0.85 (0.49-1.48) |
| | Middle tertile | 59 | 1.05 (0.63-1.75) |
| | Highest tertile | 57 | 1.61 (0.94-2.76) |
| Nonvertebral | | | |
| | Lowest tertile | 528 | 1.01 (0.85-1.20) |
| | Middle tertile | 581 | 1.01 (0.85-1.18) |
| | Highest tertile | 624 | 1.27 (1.08-1.49) |
| Clinical Spine | | | |
| | Lowest tertile | 40 | 0.89 (0.48-1.67) |
| | Middle tertile | 57 | 1.13 (0.67-1.90) |
| | Highest tertile | 51 | 1.45 (0.82-2.54) |
| Forearm/wrist | | | |
| | Lowest tertile | 90 | 0.92 (0.60-1.39) |
| | Middle tertile | 106 | 0.87 (0.59-1.27) |
| | Highest tertile | 107 | 1.41 (0.96-2.07) |
| Major osteoporotic | | | |
| | Lowest tertile | 229 | 0.90 (0.69-1.16) |
| | Middle tertile | 282 | 1.02 (0.81-1.29) |
| | Highest tertile | 279 | 1.41 (1.11-1.78) |
| Pelvic | | | |
| | Lowest tertile | 20 | 0.43 (0.16-1.11) |
| | Middle tertile | 29 | 0.61 (0.29-1.29) |
| | Highest tertile | 34 | 1.06 (0.54-2.08) |

Supplemental Table 6. Effects of Multivitamin/Multimineral Supplementation (vs. Placebo) on Incident Fracture by Self-Rated General Health, According to Fracture Location

| | • | | Hazard Ratio (95% Confidence Interval) |
|--------------------|----------------|------|--|
| Clinical | | | |
| | Excellent | 462 | 0.95 (0.80-1.15) |
| | Very good/good | 1482 | 1.13 (1.02-1.25) |
| | Fair/poor | 78 | 1.66 (1.04-2.65) |
| Hip | | | |
| | Excellent | 34 | 0.85 (0.44-1.69) |
| | Very good/good | 133 | 1.06 (0.76-1.49) |
| | Fair/poor | 11 | 2.80 (0.72-10.87) |
| Nonvertebral | | | |
| | Excellent | 431 | 0.96 (0.79-1.16) |
| | Very good/good | 1393 | 1.13 (1.02-1.26) |
| | Fair/poor | 70 | 1.72 (1.06-2.84) |
| Clinical Spine | • | | |
| | Excellent | 29 | 1.03 (0.50-2.13) |
| | Very good/good | 118 | 1.30 (0.90-1.87) |
| | Fair/poor | 13 | 1.85 (0.57-6.02) |
| Forearm/wrist | | | |
| | Excellent | 78 | 1.09 (0.70-1.70) |
| | Very good/good | 237 | 1.06 (0.82-1.37) |
| | Fair/poor | 9 | 0.93 (0.25-3.55) |
| Major osteoporotic | | | |
| | Excellent | 186 | 1.01 (0.76-1.35) |
| | Very good/good | 629 | 1.11 (0.95-1.30) |
| | Fair/poor | 39 | 1.87 (0.96-3.65) |
| Pelvic | | | |
| · | Excellent | 22 | 0.87 (0.38-2.03) |
| | Very good/good | 63 | 0.66 (0.40-1.09) |
| | Fair/poor | 4 | 3 |

-

³ Number of cases inadequate for reliable estimation of hazard ratio.